Lancashire and South Cumbria
Formulary
Formulary
4 Central nervous system
04-05-01 Anti-obesity drugs acting on the gastro-intestinal tract
| Liraglutide Saxenda® |
|
Formulary
|
6mg/ml solution for injection 3ml pre-filled pens liraglutide is recommended as an option in overweight and obesity as long as it is prescribed in secondary care by a specialist multidisciplinary tier 3 weight management service
|
 MHRA: GLP-1 receptor agonists: reports of diabetic ketoacidosis when concomitant insulin was rapidly reduced or discontinued MHRA: Ozempic▼(semaglutide) and Saxenda (liraglutide): vigilance required due to potentially harmful falsified products NICE TA664: Liraglutide for managing overweight and obesity |
|
for NICE TA749 Liraglutide for managing obesity in people aged 12 to 17 years (terminated appraisal)| Orlistat |
|
Formulary
|
| Capsules 120mg |
|
MHRA: Orlistat: theoretical interaction with antiretroviral HIV medicines |
|
| Semaglutide Wegovy® |
|
Formulary
|
Solution for injection in pre filled pen 0.25mg, 0.5mg, 1mg, 1.7mg, 2.4mg Only available via referral to a Tier 3 Weight Management Service.
|
|
MHRA: GLP-1 receptor agonists: reports of diabetic ketoacidosis when concomitant insulin was rapidly reduced or discontinued NICE TA875: Semaglutide for managing overweight and obesity |
|
|
| Tirzepatide Mounjaro® |
|
Formulary
|
Pre-filled pens, solution for injection. Managing overweight and obesity in primary care. LSCMMG has agreed that the RAG status of tirzepatide for the management of overweight and obesity will reflect the availability of tirzepatide as defined by NICE and NHS England.
It is expected that the RAG position will be updated periodically and in line with the
implementation plan. |
 LSCMMG: Tirzepatide for managing overweight and obesity position statement Tirzepatide: LSC ICB specialist weight management support in Lancashire and South Cumbria (June 2025) |
|
Links
- LSCMMG: Opioid reduction: best interests opioid reduction position statement
- LSCMMG: OpioId treatment: patient-prescriber opioid treatment agreement
- LSCMMG: Restless Legs Syndrome in Adults in Primary Care
- LSCMMG: Tirzepatide for managing overweight and obesity position statement
- MHRA Drug Safety Update Aug 2019: Naltrexone/bupropion (Mysimba): risk of adverse reactions that could affect ability to drive
- MHRA Drug Safety Update Jue 2019: GLP-1 receptor agonists: reports of diabetic ketoacidosis when concomitant insulin was rapidly reduced or discontinued
- MHRA: GLP-1 receptor agonists: reports of diabetic ketoacidosis when concomitant insulin was rapidly reduced or discontinued
- MHRA: GLP-1 receptor agonists: reports of diabetic ketoacidosis when concomitant insulin was rapidly reduced or discontinued
- MHRA: Interaction with HIV medicines
- MHRA: Orlistat: theoretical interaction with antiretroviral HIV medicines
- MHRA: Ozempic▼(semaglutide) and Saxenda (liraglutide): vigilance required due to potentially harmful falsified products
- NICE NG246: Overweight and obesity management
- NICE TA664: Liraglutide for managing overweight and obesity
- NICE TA664: Liraglutide for managing overweight and obesity
- NICE TA749: Liraglutide for managing obesity in people aged 12 to 17 years (terminated appraisal)
- NICE TA875 Semaglutide for managing overweight and obesity
- NICE TA875: Semaglutide for managing overweight and obesity
- NICETA910:Semaglutide for managing overweight and obesity in young people aged 12 to 17 years (terminated appraisal)
- Tirzepatide: LSC ICB specialist weight management support in Lancashire and South Cumbria (June 2025)